IndustryCompany release

Ascendis Q3 product revenue reaches €366M as CHMP backs TransCon CNP in achondroplasia

Ascendis Pharma, LLC · Thu 12 Nov 2026

Ascendis Pharma reported an operating profit of €125 million for Q3 2026 and a positive CHMP opinion for TransCon CNP, with an EU decision expected in Q4.

Ascendis Pharma reported third-quarter 2026 results on 12 November, with product revenue of €366 million. The company's headline title put the year-on-year increase at 89%. Operating profit for the quarter was €125 million.

YORVIPATH was the largest contributor at €291 million. SKYTROFA brought in €59 million and YUVIWEL €16 million.

On the regulatory side, the company noted positive opinions from the CHMP and the COMP for TransCon CNP in children with achondroplasia. The COMP is the EMA committee that reviews orphan designations, while the CHMP's opinion is the step that precedes a formal European Commission decision.

Ascendis expects the European Commission's final decision in the fourth quarter of 2026. It plans a first EU launch in Germany in the first quarter of 2027. The summary on file does not give further detail on the opinion, such as the approved indication wording or conditions.

What it means for your team

  • Regulatory teams tracking achondroplasia should watch for the European Commission decision, which Ascendis expects in Q4 2026.
  • Market-access teams should note that Germany is the planned first EU launch market, targeted for Q1 2027.
  • The combination of CHMP and COMP opinions signals progress on both marketing authorisation and orphan-status aspects of the TransCon CNP file.

Company's press release: Ascendis Pharma, LLC ↗

Article written by VigiEye from the official source (Ascendis Pharma, LLC). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →